Licenses targeted interventional radiotherapeutics platform
Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid organ cancers
Initial IND submission for treatment of liver cancer planned in 2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.